Abstract
Objective Determine the association between TT and breast tissue composition and breast tissue density in trans masculine individuals (TMIs).
Design This is a cross-sectional study.
Setting TMIs (n=444) underwent chest-contouring surgeries to treat their gender dysphoria between 2013 and 2019 at an urban medical center.
Participants Of the 444 TMIs, 425 had pathology images analyzed by our deep-learning algorithm to extract breast tissue composition. A subset of 42/444 TMIs had mammography prior to surgery; mammography files were available for 25/42 TMIs and analyzed using a breast density software, LIBRA.
Main Outcome(s) and Measure(s) The first outcome was the association of duration of TT and breast tissue composition assessed by pathologists (categories of lobular atrophy and stromal composition) or by our algorithm (% epithelium, % fibrous stroma, and % fat). The second outcome is the association of TT and breast density as assessed by a radiologist (categorical variable) or by LIBRA (percent density, absolute dense area, and absolute non-dense area).
Results Length of TT was associated with increasing degrees of lobular atrophy (p<0.001) but not fibrous content (p=0.821) when assessed by the pathologists. Every six months of TT was associated with decreased amounts of both epithelium (exp(β)=0.97, 95% CI 0.95-0.98, adj p=0.005) and stroma (exp(β)=0.99, 95% CI 0.98-1.00, adj p=0.051), but not fat (exp(β)=1.01, 95%CI 0.98-1.05, p=0.394) in fully adjusted models. There was no association between TT and radiologist’s breast density assessment (p=0.575) or LIBRA measurements (p>0.05).
Conclusions TT decreases breast epithelium and fibrous stroma, thus potentially reducing the breast cancer risk of TMIs. Further studies are warranted to elucidate the effect of TT on breast density and breast cancer risk.
Summary Box
Very little is known about the effect of gender-affirming testosterone therapy on cancer risks, such as breast cancer.
Epidemiological studies had different conclusions about the association between testosterone and breast cancer in cisgender women (positive association) and trans masculine individuals (inverse association).
More laboratory-based research are needed to understand the effect of testosterone on breast cancer risk in the understudied trans masculine population.
Our study provides quantitative histological evidence to support prior epidemiological reports that testosterone may reduce breast cancer risk in trans masculine individuals.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institute of Health (NIH)/National Cancer Institute (NCI) 2P50CA168504-06A1 (YJH), 1R21CA267088 (YJH and GMW), 1R56CA284564 (YJH and GMW), and R01CA240341 (LY and YJH). GMW is also supported by the Breast Cancer Research Foundation 17-174.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the BIDMC Institutional Review Board (2018P000814).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: This work was supported by the National Institute of Health (NIH)/National Cancer Institute (NCI) 2P50CA168504-06A1 (YJH), 1R21CA267088 (YJH and GMW), 1R56CA284564 (YJH and GMW), and R01CA240341 (LY and YJH). GMW is also supported by the Breast Cancer Research Foundation 17-174.
Data Availability
The source code for our deep learning networks is available at https://github.com/avellal14/BBD_Pipeline. The data that support the findings of this study are available from Dr. Jan Heng.
